IL6 and COVID-19: The same is true of a meta-analysis on IL-6 antagonists and mortality in hospitalized COVID-19 patients [96]; fungal infections were evaluated in only 5 out of 22 RCTs considered for infections, and viral reactivation was evaluated in only 1 of these 22 RCTs (20 patients).